New First-of-Its-Kind Flu Vaccine Approved by FDA Expert Panel
An FDA advisory panel has unanimously endorsed Moderna's first-of-its-kind mRNA-based seasonal influenza vaccine, mRNA-1010.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
An FDA advisory panel unanimously voted in favor of the benefit-risk profile of Moderna's mRNA-1010 seasonal influenza vaccine. FDA staff indicated that data may support its use in older adults.
Epilogue added 4d ago, after coverage quieted.
The brief
An FDA advisory committee voted unanimously in favor of the benefit-risk profile for Moderna's investigational seasonal influenza vaccine, mRNA-1010. The vaccine utilizes mRNA technology to expand the B cell response breadth in humans.
Coverage from Reuters, the Los Angeles Times, and Stat News emphasizes that the vaccine was previously subject to controversy. Reuters further notes that FDA staff indicated the vaccine's data may support use in older adults.
Market reactions are highlighted by Yahoo Finance, which reports that Moderna's stock experienced its best week in over four years following the panel's endorsement.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 19d ago.
Quick answers
What is the name of the vaccine?
The investigational seasonal influenza vaccine is designated as mRNA-1010.
How did the FDA advisory panel vote?
The panel voted unanimously in favor of the vaccine's benefit-risk profile.
What is unique about this flu vaccine?
It is a first-of-its-kind flu vaccine using mRNA technology.
Which specific population might benefit from the vaccine according to FDA staff?
FDA staff stated that data may support its use in older adults.
Coverage (9)
- Moderna flu shot data may support use in older adults, US FDA staff says Reuters · 22d ago
- Moderna just got a signal investors can’t ignore Yahoo Finance · 22d ago
- FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy statnews.com · 22d ago
- mRNA-based influenza vaccine expands the B cell response breadth in humans Nature · 22d ago
- Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine Yahoo Finance · 22d ago
- FDA panel backs first-of-its-kind flu vaccine using mRNA technology Los Angeles Times · 22d ago
- MRNA Stock Clocks Best Week In Over 4 Years On FDA Advisory Committee Endorsement For Flu Vaccine Yahoo Finance · 22d ago
- Moderna’s mRNA flu vaccine gets thumbs up from federal vaccine panel CIDRAP · 22d ago
- New First-of-Its-Kind Flu Vaccine Approved by FDA Expert Panel ScienceAlert · 22d ago
Topics
Related trends
Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
FDA moves to expose hidden foreign drug factories, strengthen domestic production in sweeping rule proposal
The FDA has introduced a proposal to consolidate registration requirements for distributed drug manufacturing networks.
FDA recalls eye drops over possible 'foreign substance'
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Millions of eye drops recalled nationwide due to potential foreign substance
The FDA has issued a nationwide recall of 2.5 million bottles of eye drops following concerns over a potential foreign substance.
Arsenic, lead and other metals in tampons aren’t harmful, FDA report concludes
The FDA has determined that trace levels of heavy metals found in tampons do not present a health risk to consumers.
FDA approves Vera Therapeutics kidney disease treatment
The FDA has approved Vera Therapeutics' dual-target drug, Trutakna, for the treatment of primary IgA nephropathy.